The classical model of hematopoiesis has long held that hematopoietic stem cells (HSCs) sit at the apex of a developmental hierarchy in which HSCs undergo long-term self-renewal while giving rise to cells of all the major blood lineages. In this model, self-renewing HSCs progressively lose self-renewal capacity as they transit into short-term self-renewing and multipotent progenitor states, with the first major lineage commitment occurring in multipotent progenitors, giving rise to progenitors that initiate the myeloid and lymphoid branches of hematopoiesis. Subsequently, within the myeloid lineage, bipotent megakaryocyte/erythrocyte and granulocyte/macrophage progenitors give rise to unipotent progenitors that ultimately give rise to all mature progeny. However, over the past several years, this developmental scheme has been challenged, with the origin of megakaryocyte precursors being one of the most debated subjects. Recent studies have suggested that megakaryocytes can be generated from multiple pathways, with some pathways not requiring transit through a requisite multipotent or bipotent megakaryocyte/erythrocyte progenitor stage. Indeed, some investigators have argued that HSCs contain a subset of cells with biased megakaryocyte potential, with megakaryocytes directly arising from HSCs under steady-state and stress conditions. In this review, we discuss the evidence supporting these non-classical megakaryocytic differentiation pathways and consider their relative strengths and weaknesses as well as the technical limitations and potential pitfalls in interpreting these studies. Ultimately, such pitfalls will need to be overcome in order to provide a comprehensive and definitive understanding of megakaryopoiesis.
Introduction
Ever since hematopoietic stem cells (HSCs) were first identified, 1 there has been great interest in developing methods to purify them in order to better understand the molecular mechanisms regulating their function. colleagues. 4 Since similar approaches can also be used to identify committed progenitors, numerous investigators have successfully isolated committed progenitor populations, leading to the development of a hierarchical model of hematopoiesis in which HSCs give rise to increasingly committed progenitors with progressively decreasing self-renewal capacity and restricted lineage potential. In this classical model of hematopoiesis, a major bifurcation occurs between the myeloid and lymphoid branches ( Figure 1A ), and restricted myeloid progenitors undergo another bifurcation into bipotent granulocyte/macrophage (GM) and megakaryocyte/erythrocyte (MegE) progenitors. [5] [6] [7] Moreover, unipotent megakaryocytic progenitor cells were placed downstream of bipotent MegE progenitors, suggesting that all megakaryocytes arise from committed precursors that are formed following requisite intermediate states. 8, 9 While the hierarchical model has been very useful for understanding hematopoiesis, it has become increasingly clear that this model is inadequate to capture all the complexities of early commitment steps in hematopoiesis, and especially in megakaryopoiesis. With advances in the ability to prospectively separate HSCs and committed progenitors as well as the development of functional and molecular assays to assess the development potential of single cells in vitro and in vivo, a more complex picture of HSC commitment to the megakaryocytic lineage has emerged in which megakaryocytes may arise directly from
HSCs as well as from multi-, bi-, and unipotent progenitors. In this review, we discuss the evidence supporting these newer models of megakaryopoiesis.
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Hematopoietic stem cells and megakaryocytes exhibit numerous similarities
It has long been appreciated that HSCs and megakaryocytes share a number of features with the most notable being their shared expression of, and dependence on, the thrombopoietin (TPO) receptor (MPL) for their maintenance and expansion (reviewed by Huang and Cantor 10 ) . Indeed, studies of MPL deficient mice identified defects in the ability of bone marrow to long-term reconstitute irradiated recipients, 11 and additional studies have
showed that TPO/MPL signaling is important to maintain HSC quiescence. 12 18 Whether or not these individual cells were derived from multipotent, selfrenewing HSCs, committed progenitors derived from HSCs, or other origin was not addressed functionally, but these studies raised the possibility that HSCs and megakaryocyte progenitors are closer to one another in the hematopoietic developmental hierarchy than previously appreciated.
Perhaps it is not that surprising that HSCs and megakaryocytes share so many similarities.
Given the requirement for multicellular organisms to develop strategies to rapidly generate platelets to protect the integrity of the vascular systems, it is possible that the generation of HSCs and platelets are linked. Although this explanation is speculative, co-evolution of immunity and hemostasis can be seen even in invertebrates, where cellular mediators of For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From hemostasis, so-called "hemocytes" evolved to protect the host from invading microbes as well as prevent "blood" (i.e. hemolymph) loss following injury by triggering coagulation. 19, 20 In mammals, megakaryocytes and red cells (and macrophages) appear at the same time during development with the appearance of primitive hematopoiesis in the yolk sac. 21, 22 It is also noteworthy that the endothelial and hematopoietic lineages share a common embryonic precursor, the hemangioblast 23 , with the majority of hemangioblast precursors exhibiting megakaryocyte potential 24 . This may explain why many of the factors commonly expressed by megakaryocytes and HSCs (e.g. Von Willebrand Factor, or vWF) are also expressed by endothelial cells and hemangioblasts. 10 The overlapping and interrelated roles of endothelial cells and megakaryocytes are illustrated in hemostasis, in which platelets function to close disrupted endothelium after injury. In addition, the thrombomodulin/activated protein C pathway -important in anticoagulation 25 -is also important for hematopoietic recovery after irradiation.
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Lymphoid-primed multipotent progenitors and early loss of megakaryocyte potential
The identification of common myeloid progenitors (CMPs) 5, 7 and common lymphoid progenitors (CLPs) 27 resulted in a model of hematopoiesis in which the first lineage commitment step downstream from HSCs occurred at the segregation of the myeloid and lymphoid lineages. In the myeloid branch, CMPs gave rise to two more restricted progenitors, megakaryocyte/erythrocyte progenitors (MEPs) and granulocyte/macrophage progenitors (GMPs), 5 with MEPs giving rise to erythroid progenitors and unipotent megakaryocytic precursors ( Figure 1A ). 34 However, these latter studies should be interpreted with care, since differentiation was highly dependent on the culture conditions used. While the classical model of bifurcated myeloid and lymphoid lineages was now challenged, a number of questions remained, including the relationship between LMPPs and CMPs and whether
LMPPs represent a heterogeneous population of cells with differences in lineage potential.
Indeed, multiplex single cell PCR revealed that LSKFlt3 + cells co-express IL-7Rα and G-CSFR, but this was only true for approximately 6% of the analyzed cells. 38 Taken together, these studies strongly supported the existence of a MPP population with lymphoid and GM potential without MegE potential, representing an early step in lineage commitment. However, rather than a sudden loss of MegE potential, it is more likely that there is a gradual decrease in the ability to commit to these lineages, coinciding with an increase in lymphoid priming. 39 Thus, in this model LMPPs mainly give rise to CLPs and GMPs, but still exhibit limited MegE potential ( Figure 1C) 
Stem cell commitment to megakaryocyte differentiation
It has become increasingly evident that even the most immature LT-HSC pool is functionally heterogeneous. 41 In fact, myeloid-biased, lymphoid-biased, and myeloid-lymphoid balanced HSC subsets have been identified [42] [43] [44] [45] , and such lineage biased HSCs can be prospectively separated based on differential expression of CD150/SlamF1. 46 Previous studies have also 47 Unfortunately, neither of these studies evaluated megakaryocyte or erythroid output from these functionally defined HSC subsets.
The identification of LMPPs suggested that a committed MegE-committed progenitor directly arises from a ST-HSC or early MPP without passing through a requisite CMP intermediate.
These studies also demonstrated an inverse correlation between the degree of differentiation and the time to give rise to mature myelomonocytic and lymphoid cells (i.e. faster myeloid cell production from CMP compared to LT-HSC). However, this relationship between degree of differentiation and time until detection of mature cells in vivo was not observed for platelets. 36 Instead, platelets from all populations with megakaryocyte potential were detected at the same time, suggesting that there might be a "short-cut" along the differentiation route from HSC to megakaryocyte. While such an interpretation is reasonable, it should be made with caution since it can be difficult to measure the emergence of cells of the various lineages from small numbers of cells, especially at early time points.
Evidence for a megakaryocyte-biased population of HSCs was presented by the Jacobsen group using transgenic mice with a GFP reporter driven by the megakaryocyte associated vWF gene. 48 For Direct transition from a HSC to a unipotent megakaryocyte progenitor seems to be in conflict with studies that indicate that all hematopoietic lineages develop from Flt3 + progenitors. 52, 53 In studies supporting a direct transition, a dual-color reporter mouse model was utilized that 
Megakaryocytes in the hematopoietic stem cell niche
The importance of the niche in regulating HSC function is well appreciated and a role for megakaryocytes in the niche has been suggested. [55] [56] [57] [58] Two recent studies have demonstrated that megakaryocytes likely contribute to the HSC niche since in vivo megakaryocyte ablation result in a loss of HSC quiescence. 59, 60 As HSCs are in close proximity to megakaryocytes in the bone marrow, and no changes were observed in other cellular niche components, these effects appear to be due to direct effects of megakaryocytes on HSCs. 59 This effect appears to be mediated in part by TGF-β, as TGF-β 1 injection rescued HSC quiescence in megakaryocyte-depleted mice, and genetic deletion of Tgfb1 in megakaryocytes resulted in similar effects to their ablation. 60 This phenotype may also be mediated in part by CXCL4, a factor known to regulate HSC quiescence and produced by megakaryocytes, as CXCL4 administration to megakaryocyte-depleted mice partially rescued the HSC defect. 59 Taken together, these data demonstrate a direct role for megakaryocytes in HSC regulation, and raise the possibility that megakaryocytes provide direct feedback to HSCs, thereby controlling their own replenishment. Indeed, under stress conditions such as after chemotherapeutic treatment, the role of megakaryocytes might switch to promote HSC proliferation and expansion, possibly by FGF1 secretion. 60 It would be interesting to determine whether this feedback mechanism promotes megakaryocyte/platelet production by regulating multipotent HSCs or preferentially stimulates megakaryocytic-biased HSCs. In the latter case, one might hypothesize that platelet-biased HSCs may occupy distinct niches in which megakaryocytes play an important supportive role.
For Figure 1C ). But how accurate is this model? In our opinion, a number of technical pitfalls and conceptual concerns must be addressed first before a definitive model of megakaryopoiesis can be formulated.
At least two biases/pitfalls have strongly influenced the development of newer models of megakaryopoiesis. The first is common to nearly all studies, namely a reliance on cell surface immunophenotypes to identify candidate HSC and committed progenitor populations.
Given the HSC field's relentless pursuit of identifying more highly enriched HSC populations based on cell surface antigens 2, 3 , perhaps it is not surprising that this has led investigators to assume that cell populations with immunophenotypes similar to HSCs should be composed of cells with similar function. However, this assumption may not hold true for megakaryocytic progenitors, as exemplified by the presence of so-called "megakaryocyte-biased
HSCs". 45, 46, 48 This potential bias can be addressed by identifying additional markers to prospectively separate distinct HSC subsets, such as described for myeloid-and lymphoid biased HSCs. While single-cell transplant assays have helped to characterize the diversity of outcomes for HSC-enriched populations, the inability to prospectively separate these subsets makes it difficult to determine whether the variable lineage potential is due to "contamination" by committed progenitors within the immunophenotypically defined HSC pool, or due to intrinsic lineage bias of single HSCs themselves. The identification of markers that allow separation of clonally distinct, immunophenotypically defined "HSCs" and characterization of their hierarchical relationships could help distinguish between these possibilities. Thus, increased efforts to identify such markers are warranted.
It is important to note that many of the unresolved questions with respect to early megakaryocytic commitment remain due to differences in the cell populations evaluated (i.e.
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From using different immunophenotypes to identify HSCs) and the nature of the assays employed (e.g. in vitro versus in vivo, clonal versus population based). Ultimately, it will be important for investigators to use similar strategies, whether using identical cell surface phenotypes or genetic reporters to identify HSCs, in order to resolve differences in experimental results and interpretations. Even if these factors are controlled for, investigators will still have to contend with the pitfalls of in vitro and transplantation assays used to functionally evaluate hematopoietic stem and progenitor cells. In vitro assays, by their very nature, likely do not accurately reflect normal physiologic conditions, and in vivo transplantation assays are typically performed in irradiated animals, which can induce significant changes in hematopoietic output. 61 Thus, it will be important to develop methods to study endogenous hematopoietic differentiation at the clonal level in defined HSC/progenitor cell populations.
Clonal assays will remain the preferred method to evaluate engraftment and lineage outcomes of candidate HSC/progenitor populations since they can quantitatively and qualitatively evaluate differences in megakaryocyte potential in heterogeneous cell populations. However, these assays may be difficult to interpret since platelet production may be transient and below the limit of detection. This is an important concern since platelets are frequently not evaluated until at least two weeks after transplant, at which time non-selfrenewing megakaryocytic progenitors likely are no longer present or give rise to platelets. 36 Since some immunophenotypically defined HSCs may be able to commit to the megakaryocyte lineage almost immediately, it will be important to assess commitment to the megakaryocytic lineage at earlier time points during differentiation assays, even prior to cell However, this approach would be very challenging since current methods likely would not be sufficiently sensitive to detect such small numbers of progeny from single cell transplants.
Finally, it is important to note that most of the studies that have rigorously assessed the earliest steps in megakaryocyte lineage commitment were conducted in the mouse system. While a putative human LMPP was identified using a combination of in vitro culture and xenotransplantation assays, 62 whether human megakaryopoiesis includes megakaryocyticbiased HSC in addition to bipotent and unipotent megakaryocytic progenitors has yet to be investigated. One of the gene expression studies indicating a close relationship between HSCs and MegE progenitors was performed in human cord blood and peripheral blood, suggesting that the observations in the murine system might also be true for human 17 , but, at present, the concept of lineage-biased HSCs has not been confirmed in the human system. 2 We look forward to future studies that assess whether human and mouse hematopoiesis exhibit similar properties with respect to these early steps in megakaryopoiesis, including the development of experimental systems that allow in vivo clonal tracking of single human
HSCs and committed progenitors in the xenotransplantation setting.
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